TITLE

COMMENTARY: Review: Selective COX-2 inhibitors increase vascular events more than placebo and naproxen, but not more than other NSAIDs

AUTHOR(S)
Laupacis, Andreas
PUB. DATE
November 2006
SOURCE
ACP Journal Club;Nov/Dec2006, Vol. 145 Issue 3, p66
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents the author's comments on a medical study that finds effects of selective cyclooxygenase-2 (COX-2) inhibitors on vascular events. The study revealed that the COX-2 inhibitors increase vascular events more than placebo and naproxen. Another important aspect of this study is that it revealed traditional nonsteroidal anti-inflammatory agents cause an increase in vascular events that seems similar to that of COX-2 inhibitors.
ACCESSION #
23245693

 

Related Articles

  • Review: Selective COX-2 inhibitors increase vascular events more than placebo and naproxen, but not more than other NSAIDs.  // ACP Journal Club;Nov/Dec2006, Vol. 145 Issue 3, p66 

    The article presents information on a medical study that finds effects of selective cyclooxygenase-2 (COX-2) inhibitors on vascular events. Randomized controlled trials of four weeks in duration that compared a selective COX-2 inhibitor with placebo or a traditional non-steroidal...

  • A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273]. Collantes, Eduardo; Curtis, Sean P.; Ka Wing Lee; Casas, Noemi; McCarthy, Timothy; Melian, Agustin; Zhao, Peng L.; Rodgers, Diana B.; McCormick, Calogera L.; Lee, Michael; Lines, Christopher R.; Gertz, Barry J. // BMC Family Practice;2002, Vol. 3, p10 

    Background: Etoricoxib is a highly selective COX-2 inhibitor which was evaluated for the treatment of rheumatoid arthritis (RA). Methods: Double-blind, randomized, placebo and active comparator-controlled, 12-week study conducted at 67 sites in 28 countries. Eligible patients were chronic NSAID...

  • Review: non-steroidal anti-inflammatory drugs reduce menstrual pain and heavy bleeding associated with an intrauterine device. Serrant-Green, Laura // Evidence Based Nursing;Apr2007, Vol. 10 Issue 2, p48 

    The article presents information on a medical research which concluded that non-steroidal anti-inflammatory drugs (NSAID) can decrease menstrual pain and heavy bleeding associated with an intrauterine device. NSAID decreased menstrual blood loss more that placebo in 3 of 4 trials but did not...

  • Rethinking osteoarthritis pain management-a practical approach. Askari, Ali; Eisenberg, Gerald // Patient Care;Nov2005, Vol. 39 Issue 11, p60 

    The article discusses the clinical management of pain and loss of function associated with osteoarthritis. The use of selective cyclooxygenase-2 inhibitors and other non-steroidal anti-inflammatory drugs have raised safety concerns and controversies. The treatment of patients with osteoarthritis...

  • Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. A. I. Sebba; B. R. Rubin; G. E. Ruoff; J. Kremer; S. Bird; S. S. Smugar; B. J. Fitzgerald; K. O’Brien; A. M. Tershakovec // Rheumatology;Mar2007, Vol. 46 Issue 3, p496 

    Objective. To compare the efficacy of etoricoxib 30 mg with the generally maximum recommended dose of celecoxib, 200 mg, in the treatment of osteoarthritis (OA) in two identically designed studies.Methods. Two multi-centre, 26-week, double-blind, placebo-controlled, non-inferiority...

  • Adverse Reaction Research.  // Reactions Weekly;12/6/2008, Issue 1231, p3 

    A conference paper about COX-2 inhibitors in subjects for whom blood pressure (BP) data were available is presented. It states that compared with placebo, the risk of developing new hypertension was increased with COX-2 inhibitors and this was driven largely by the increased risk associated with...

  • Prescribing COX-2 inhibitors. Newson, Louise // GP: General Practitioner;12/8/2006, p42 

    The article presents information on clinical trials examining the association of COX-2 inhibitors with the cardiovascular events. One of the trials has suggested that celecoxib is associated with an excess of cardiovascular events. Another trial has indicated that COX-2 inhibitors and high-dose...

  • Celecoxib Shown Effective in Preventing Colon Polyps. Nelson, Nancy J. // JNCI: Journal of the National Cancer Institute;5/17/2006, Vol. 98 Issue 10, p665 

    The article reports on the effect of celecoxib on colon polyps. Celecoxib is effective in preventing the development of colon polyps and rectal polyps. The claim is base on two clinical trials. Celecoxib is a cyclooxygenase 2 (COX-2) inhibitor that is in the nonsteroidal anti-inflammatory drugs...

  • NSAID Use in Individuals alt Risk of Renal Adverse Events. Roughead, Elizabeth E.; Ramsay, Emmae; Pratt, Nicole; Gilbert, Andrew L. // Drug Safety;2008, Vol. 31 Issue 11, p997 

    Background: Cyclo-oxygenase (COX)-2 inhibitors were introduced to world markets with claims of improved gastrointestinal safety compared with traditional NSAIDs. Randomized clinical trials had demonstrated fewer adverse gastrointestinal events with COX-2 inhibitors, but no difference with other...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics